Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Youre at risk of vitamin B12 deficiency
doi: 10.3402/gha.v8.25709 111
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
As an pro-angiogenic agent, it's theoretically possible for BPC-157 to enable cancers to grow
Combination-Protocol Research Beyond the individual studies referenced above, several published research lines have specifically investigated BPC-157 and TB-500 in combination : Combined BPC-157 + TB-500 in musculoskeletal injury models searches across rodent rotator-cuff, Achilles tendon and ligament transection research
